Post by Grifols

GigaGen, a subsidiary of Grifols, will present clinical data for GIGA-564 for the first time at the AACR Annual Meeting 2026, one of the leading global forums in oncology research. The poster will share preliminary results from a first-in-human Phase 1 study of GIGA-564, a non-blocking anti-CTLA-4 antibody designed to deplete intratumoral regulatory T cells (Tregs) in patients with advanced or metastatic solid tumors. The study will be presented by James Gully, MD, PhD, from the National Cancer Institute.   📅 April 20, 2026 ⏰ 2:00 PM (PT) 📍 San Diego, U.S. More information 👉 https://lnkd.in/gV787au8 #AACR2026